HIF1A and neoplasm: Strikingly, the combination of FDA-approved CDK4/6 inhibitors and HSP90 inhibitors showed enhanced inhibition of HIF-1 activity and synergistic anti-tumor effects in models of renal and colon cancer lacking VHL and Rb [7].